United Kingdom (UK)
Recombinant monoclonal antibody to S protein (RBD). Manufactured using AbAb’s Recombinant Platform with variable regions (i.e. specificity) from the phage display antibody 1E2.
UniProt Accession Number of Target Protein: P0DTC2
Alternative Name(s) of Target: SARS CoV 2 S glycoprotein; COVID-19 Spike protein; RBD; Receptor Binding Domain; E2 glycoprotein; E2; Human coronavirus 2 spike glycoprotein; Peplomer protein; S glycoprotein; SARS coronavirus 2 S protein; SARS coronavirus 2 Spike Protein; SARS CoV 2 Spike protein; SARS CoV 2; SARS-CoV-2 S protein; SARSCoV2; SARS-COV-2 S protein; SARS-COV-2 Spike glycoprotein; SARSCOV2 Spike protein; Severe acute respiratory syndrome 2 spike glycoprotein; Severe acute respiratory syndrome virus 2 spike glycoprotein; Spike glycoprotein; 2019-nCoV; SARS-CoV2
Immunogen: The original antibody was generated from a panel of humanized single domain antibodies derived from a synthetic library. The antibody was isolated by panning against SARS-CoV-2 spike receptor-binding domain (RBD).
Specificity: The antibody binds to the RBD of the Spike protein of SARS-CoV.
Application Notes: The specificity of the original format of the antibody was confirmed by ELISA analysis. The binding affinity of the VHH fragment to SARS-CoV-2 RBD was measured by surface plasmon resonance (Kd= 35.5 nM). The VHH showed half maximal neutralization concentration (EC50) of 0.069 µg/mL and 0.2401 µg/mL against SARS-CoV-2 pseudotypes, and authentic SARS-CoV-2, respectively. Fusion of the human IgG1 Fc to the VHH improved the neutralizing activity compared to the original format of the antibody. The Fc-fused VHH demonstrated potency with EC50 of 0.538 nM. (Chi et al, 2020; pmid: 32913273)
Antibody first published in:
Chi et al. Humanized single domain antibodies neutralize SARS-CoV-2 by targeting the spike receptor binding domain. Nat Commun. 2020 Sep 10;11(1):4528. PMID:32913273
Note on publication:
The original paper describes the generation and characterization of the antibody.